WuXi AppTec
Search results
Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.
$Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
微生物. 大肠杆菌及酵母表达系统，一体化CMC开发及cGMP生产微生物发酵平台. 质量. 通过FDA, EMA 和 NMPA认证的一流质量体系. 病毒. 全球化一站式CMC开发,多个在建或已投产的cGMP基地用于生产病毒产品及疫苗. 全球布局. 预计到2026年后，公司在中国、爱尔兰、美国、德国和新加坡规划的生物制药生产基地合计产能将超过58万升。 美国. 伍斯特. 美国. 18.95万 平方英尺. 产能 3.6万升. learn more. 新泽西. 美国. 1.4万+ 平方米. 运营于 2021年. learn more. 宾夕法尼亚州普鲁士王市. 美国. 0.3万+ 平方米. 运营于 2020年. learn more. 波士顿.
Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations...
Jul 21, 2022 · SINGAPORE - Chinese companies WuXi Biologics and WuXi AppTec will be investing up to $4 billion in total in Singapore to grow their research and development (R&D) and manufacturing...
Mar 19, 2024 · WuXi Biologics announced a USD$1.4 billion (S$2 billion) investment in Singapore in 2022. The CRDMO center will be the first-of-its-kind in Singapore, offering end-to-end biologics research, development and manufacturing solutions upon completion.
Jul 19, 2022 · WuXi Biologics (stock code: 2269.HK) is a global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide.
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
Aug 3, 2022 · China’s WuXi Biologics has announced a 10-year investment plan aimed at establishing a world-class pharmaceutical contract manufacturing center in Singapore. The Singapore Economic Development Board (EDB) is supporting the project.
